Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- JNCE
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Jounce Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 98.95M
- Ent value
- -22.18M
- Price/Sales
- 1.21
- Price/Book
- 0.54
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 12.49%
- 1 year return
- -63.98%
- 3 year return
- -29.39%
- 5 year return
- -37.78%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
JNCE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 23.07 |
| Price to FCF | 3.11 |
| Price to EBITDA | 2.47 |
| EV to EBITDA | -0.55 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.21 |
| Price to Book | 0.54 |
| EV to Sales | -0.27 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 52.64M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -1.03 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 150.57M |
| Net receivables | 0.00 |
| Total current assets | 197.23M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 212.55M |
| Accounts payable | 19.24M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 23.57M |
| Total liabilities | 29.44M |
| Shareholder's equity | 183.11M |
| Net tangible assets | 183.11M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| JNCE | S&P500 | |
| Current price drop from All-time high | -93.39% | -13.62% |
| Highest price drop | -97.75% | -19.00% |
| Date of highest drop | 12 Dec 2022 | 8 Apr 2025 |
| Avg drop from high | -69.79% | -2.76% |
| Avg time to new high | 105 days | 5 days |
| Max time to new high | 1515 days | 89 days |
COMPANY DETAILS
Marketcap
98.95M
Marketcap category
Small-cap
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Employees
141
Website
Investor relations
-
SEC filings
CEO
Richard Murray
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner